Importantly, the normal phenotype of KLB null mice, coupled with the restricted tissue expression of KLB [14-16], suggests that systemic treatment with KLB inhibitors should have minimal risk of toxic effects in HCC patients. The gene discussed is KLB; the disease is hepatocellular carcinoma.